Nektar Total Current Liabilities from 2010 to 2024
| NKTR Stock | USD 1.29 0.03 2.38% |
Total Current Liabilities | First Reported 1994-03-31 | Previous Quarter 51.3 M | Current Value 52.4 M | Quarterly Volatility 67.2 M |
Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.4 M, Interest Expense of 23.9 M or Total Revenue of 162.3 M, as well as many indicators such as Price To Sales Ratio of 1.13, Dividend Yield of 0.0 or PTB Ratio of 0.78. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.
Nektar | Total Current Liabilities |
Latest Nektar Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Nektar Therapeutics over the last few years. Total Current Liabilities is an item on Nektar Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nektar Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Nektar Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nektar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Nektar Total Current Liabilities Regression Statistics
| Arithmetic Mean | 103,451,676 | |
| Geometric Mean | 69,400,989 | |
| Coefficient Of Variation | 87.64 | |
| Mean Deviation | 57,979,863 | |
| Median | 78,537,000 | |
| Standard Deviation | 90,667,448 | |
| Sample Variance | 8220.6T | |
| Range | 352.5M | |
| R-Value | (0.02) | |
| Mean Square Error | 8850.6T | |
| R-Squared | 0.0003 | |
| Significance | 0.95 | |
| Slope | (330,129) | |
| Total Sum of Squares | 115088.2T |
Nektar Total Current Liabilities History
About Nektar Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Nektar Therapeutics income statement, its balance sheet, and the statement of cash flows. Nektar Therapeutics investors use historical funamental indicators, such as Nektar Therapeutics's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may use each financial statement separately, they are all related. The changes in Nektar Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nektar Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Nektar Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Nektar Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 51.3 M | 88.1 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.